Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer

BACKGROUND: Gemogenovatucel-T (Vigil) is a triple-function autologous tumor cell immunotherapy which expresses granulocyte-macrophage colony-stimulating factor and decreases expression of furin and downstream TGF-β1 and TGF-β2. Vigil has suggested survival benefit in frontline maintenance ovarian ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Barve, Minal, Aaron, Phylicia, Manning, Luisa, Bognar, Ernest, Wallraven, Gladice, Horvath, Staci, Stanbery, Laura, Nemunaitis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358582/
https://www.ncbi.nlm.nih.gov/pubmed/35957960
http://dx.doi.org/10.1177/11795549221110501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358582/
https://www.ncbi.nlm.nih.gov/pubmed/35957960
http://dx.doi.org/10.1177/11795549221110501

Ejemplares similares